<DOC>
	<DOC>NCT01492361</DOC>
	<brief_summary>AMR101 (icosapent ethyl [ethyl-EPA]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) being developed by Amarin Pharma Inc. for the treatment of hypertriglyceridemia. The purpose of this study is to evaluate whether this drug, combined with a statin therapy, will be superior to the statin therapy alone, when used as a prevention in reducing long-term cardiovascular events in high-risk patients with mixed dyslipidemia.</brief_summary>
	<brief_title>A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Eicosapentaenoic acid ethyl ester</mesh_term>
	<criteria>Men and nonpregnant or sterile women ages 45 and older Hypertriglyceridemia On statin therapy for at least four weeks Either having established Cardiovascular Disease or at high risk for Cardiovascular Disease Severe heart failure Any lifethreatening disease other than Cardiovascular Disease Active severe liver disease Hemoglobin A1c &gt;10.0% Poorly controlled hypertension Planned coronary intervention (such as stent placement or heart bypass) or any noncardiac major surgical procedure Known familial lipoprotein lipase deficiency (Fredrickson Type I), apolipoprotein CII deficiency, or familial dysbetalipoproteinemia (Fredrickson Type III) Known hypersensitivity to the study product, fish and/or shellfish, or placebo History of acute or chronic pancreatitis Patients are excluded if using the following medications: niacin &gt;200 mg/day or fibrates; any omega3 fatty acid medications ; dietary supplements containing omega3 fatty acids (e.g., flaxseed oil, fish oil, krill oil, or algal oil); bile acid sequestrants</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Myocardial Ischemia</keyword>
	<keyword>Coronary Disease</keyword>
	<keyword>Heart Diseases</keyword>
	<keyword>Acute Coronary Syndrome</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Arteriosclerosis</keyword>
	<keyword>Arterial Occlusive Diseases</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Angina Pectoris</keyword>
	<keyword>Chest Pain</keyword>
	<keyword>Anticholesteremic Agents</keyword>
	<keyword>Hypolipidemic Agents</keyword>
	<keyword>Lipid Regulating Agents</keyword>
	<keyword>hypertriglyceridemia</keyword>
	<keyword>omega-3 fatty acids</keyword>
	<keyword>statin</keyword>
	<keyword>triglycerides</keyword>
	<keyword>EPA</keyword>
	<keyword>docosahexaenoic acid</keyword>
	<keyword>fish</keyword>
	<keyword>fatty acids</keyword>
	<keyword>fibrates</keyword>
	<keyword>niacin</keyword>
	<keyword>lipids</keyword>
	<keyword>lipoprotein</keyword>
	<keyword>atorvastatin</keyword>
	<keyword>Lovaza</keyword>
	<keyword>simvastatin</keyword>
	<keyword>lovastatin</keyword>
	<keyword>pravastatin</keyword>
	<keyword>fluvastatin</keyword>
	<keyword>rosuvastatin</keyword>
	<keyword>Trilipix</keyword>
	<keyword>Vytorin</keyword>
	<keyword>Simcor</keyword>
	<keyword>ezetimibe</keyword>
	<keyword>Zetia</keyword>
	<keyword>ethyl-EPA</keyword>
	<keyword>ethyl icosapentate</keyword>
	<keyword>Crestor</keyword>
	<keyword>Zocor</keyword>
	<keyword>Lipitor</keyword>
	<keyword>LDL</keyword>
	<keyword>HDL</keyword>
	<keyword>cholesterol</keyword>
	<keyword>dyslipidemia</keyword>
	<keyword>AMR101</keyword>
	<keyword>Cardiovascular Disease, Unspecified</keyword>
	<keyword>VASCEPA</keyword>
	<keyword>icosapent ethyl</keyword>
</DOC>